100
Participants
Start Date
September 30, 2008
Primary Completion Date
November 30, 2011
Study Completion Date
January 31, 2014
Dasatinib
Tablets, Oral, 100 mg, once daily (QD), upto 2 years
Fulvestrant
Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
New York Oncology Hematology, Pc, Troy
Virginia Center Specialists, Pc, Woodbridge
Virginia Oncology Associates, Norfolk
Oncology & Hematology Associates Of Southwest Virginia, Inc., Salem
Raleigh Hematology Oncology Associates, Raleigh
Cancer Centers Of Florida, P.A, Ocoee
Central Indiana Cancer Centers, Carmel
Minnesota Oncology Hematology, P.A., Minneapolis
Missouri Cancer Associates, Columbia
Kansas City Cancer Center, Llc., Overland Park
Texas Oncology, Dallas
Texas Oncology Sammons Cancer Center, Dallas
Tyler Cancer Center, Tyler
Texas Oncology, P.A., Bedford
Texas Cancer Center, Denton
Texas Oncology Cancer Care And Research Center, Waco
Us Oncology Research, Inc., Houston
Quest Diagnostic Clinical Laboratories Inc, Houston
Cancer Care Centers Of South Texas, San Antonio
Texas Oncology-Central Austin Cancer Center, Austin
El Paso Cancer Treatment Ctr - West, El Paso
Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson
Northwest Cancer Specialists, P.C., Portland
Willamette Valley Cancer Center, Eugene
Northern Arizona Hematology & Oncology Associates, Sedona
Florida Cancer Institute - New Hope, Hudson
Texas Oncology, P.A., Dallas
Texas Oncology, P.A., Webster
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY